DIRS.INFO The most relevant business & tech news

☆ Jim Gaffigan lost 50 pounds and says gardening helps him eat healthier
▼ + stars: | 2024-11-20 | by ( Erin Liam | ) www.businessinsider.com time to read: +3 min

AdvertisementBesides taking Mounjaro, a weight-loss drug, Jim Gaffigan found that gardening benefited his health. He said gardening encouraged him to eat healthier and helped him achieve his fitness goals. Advertisement"I've always been kind of a compulsive eater," he said in the magazine's "Eat Like" video segment. "Big thing that made me eat healthier is I started gardening," he added. Since his doctor suggested taking the drug two years ago, Gaffigan has lost 50 pounds.

Persons: Jim Gaffigan, Jim Gaffigan's, Gaffigan, we've, I'm, Rebecca Harrington, breadcrumbs, Naomi Whittel Organizations: Men's, Business Insider Locations: Instagram

☆ Wegovy/Mounjaro: The UK thinks weight loss drugs could ease unemployment. Experts say that’s a fantasy
▼ + stars: | 2024-11-17 | by ( Lauren Kent | ) edition.cnn.com time to read: +8 min

London CNN —Weight loss drugs such as Wegovy and Ozempic have been hailed worldwide as revolutionary for medicine. Additional measures to prevent obesity in the first place are desperately needed, health experts say. Part of that new thinking is exploring weight loss drugs. The OHA has crunched the numbers on existing weight loss drugs like Wegovy, the brand name for the appetite suppressant semaglutide. “There is no such thing as a silver bullet for obesity,” the Obesity Health Alliance emphasized.

Persons: Wes Streeting, Streeting, Eli Lilly, It’s, Keir Starmer, ”, Alfred Slade, suppressant, ” Slade, “, it’s, Tom Little, prioritization, Jack Doughty, Martin White, ” White, White Organizations: London CNN, National Health Service, The Telegraph, Survey, British, Obesity Health Alliance, OHA, CNN, Reuters, Diabetes UK, NHS, of Health, Social Care, University of Cambridge Locations: United Kingdom, England, Novo Nordisk's, Denmark, sodas

☆ Lost and found: Life after Ozempic and other weight-loss drugs was just the start for these four people
▼ + stars: | 2024-11-16 | by ( Carma Hassan | Zoe Todd | ) edition.cnn.com time to read: +19 min

The 22-year-old content creator approached her doctor about weight loss medication in March, before she had breast reduction surgery. Method: Zepbound, diet changes, exerciseZepbound, diet changes, exercise Duration: Took Zepbound from May to October. “The breast reduction was a big step, but the weight loss put a little cherry on top,” she said. Method: Compounded semaglutide, diet changes, exerciseCompounded semaglutide, diet changes, exercise Duration: Took compounded semaglutide from February to May. Method: Ozempic, diet changes, exerciseOzempic, diet changes, exercise Duration: Took Ozempic from May 2020 to October 2023“I was very close to being 300 pounds.

Persons: Sanjay Gupta, ”, Eduardo Grunvald, Alexus Murphy, CNN Alexus Murphy, Alexus, Murphy, It’s, it’s, “, ” Murphy, Alexus Murphy She’s, “ It’s, “ I’m, you’re, Steven Ray, Ray, he’s, ” Ray, Becky Bell, CNN Becky Bell, she’s, Bell, ” “, ” Ozempic, Max Nazaire, ” Bell, Nazaire, She’s, Ozempic, Dustin Gee, CNN Dustin Gee, didn’t, I’ve, –, ” Gee, Gee, ‘, Cristian, Emanuel, Jackson, Alex, Gee's, Dr, CNN’s Tal Yellin Organizations: CNN, CNN — Research, University of California, BMI, Houston, Inland, Health, Medi, Cal, US Food and Drug Administration, FDA, “, Bell, Ozempic, Mayo Clinic Diet, Get CNN, CNN Health Locations: San Diego, California, Houston, Woodstock , Georgia, Safe Haven, Peru, Bellingham , Massachusetts, Lima

☆ 5 new weight-loss drugs to watch in the fight for the next Ozempic
▼ + stars: | 2024-11-16 | by ( ) www.businessinsider.com time to read: +8 min

"Forthcoming medications take the blockbuster GLP-1 medications and up the ante." Like semaglutide (the active ingredient in Ozempic and Wegovy), it works on GLP-1, a hormone that regulates blood sugar and appetite. CagriSema adds it to the already-popular drug semaglutide, which itself helps manage hunger and blood sugar levels. "Longer-acting versions of GLP-1 medications offer the potential for greater convenience and potentially improved adherence and sustained use over time," McGowan said. Timeline: Data from Phase II trials is expected later this year, and planning is underway for Phase III trials.

Persons: Eli Lilly, Dr, Christopher McGowan, Eli Lilly's, Ozempic, retatrutide, VK2735, we've, they're, McGowan Organizations: Pharma, Novo Nordisk, Viking Therapeutics, Triple, Therapeutics, FDA, orforglipron, Nordisk, Reuters Locations: GLP, Mounjaro, California

☆ Blockbuster weight loss drugs are revealing what we still don’t understand about obesity
▼ + stars: | 2024-11-15 | by ( Dr. Sanjay Gupta | ) edition.cnn.com time to read: +10 min

Or any of the blockbuster weight loss and diabetes drugs that recently caught the world’s attention? The joy of foodHolst is also very focused on this particular mechanism of the GLP-1 drugs but worries that it can go too far. For others, it is the loss of lean muscle mass that accompanies their weight loss and puts them at greater risk for falls. Because the medications work by slowing digestion, terrible constipation becomes a side effect that is too much for some to bear. There is little doubt that for most people, regular exercise and eating right is still the best strategy for weight loss and overall health.

Persons: Sanjay Gupta, Jens Juul Holst, Holst, CNN Holst, Karin Conde, ” Conde, Knape, –, ”, Dr Organizations: CNN, Novo Nordisk, American Medical Association, World Health Organization, BMI, CNN Health Locations: Copenhagen, Danish, United States, “

☆ How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
▼ + stars: | 2024-11-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Shares of obesity drugmaker Eli Lilly fell more than 4% on Friday, extending a roughly 3% slide in Thursday's session. Ozempic is the posterchild of the fast-growing GLP-1 class, in which Novo Nordisk and Eli Lilly are currently the two dominant players. Bottom line Eli Lilly has been our favorite drug stock for years thanks to its stellar pipeline led by GLP-1s. But, at this point, Kennedy's nomination requires us to be more cautious on Eli Lilly in the near term. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, Donald Trump, Robert F, Kennedy Jr, Kentucky Sen, Rand Paul, Kennedy, Trump, Eli Lilly's, John F, Kennedy —, LLY, Eli Lilly's GLP, Jim Cramer, David Ricks, Lilly, It's, Jim, it's, Jim Cramer's, Cristina Arias Organizations: Republican, Department of Health, Human Services, HHS, and Drug Administration, Centers for Disease Control, Medicare, Medicaid, Senate, Democratic, GOP, Media, Novo Nordisk, Moderna, Pfizer, Deutsche Bank, GSK, White, CDC, Street Journal, GLP, Big Pharma, FDA, tirzepatide, CNBC, Company, Pharmaceutical Locations: Washington, Kentucky, Danish, U.S, Alcobendas, Madrid, Spain

Here's a rapid-fire update on all the stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. This time around, Trump's tariff proposals on Chinese imports could help Amazon in its competition against low-price online sellers Temu and Shein. Salesforce : Not a Trump stock, but it wasn't a Kamala Harris stock either. Constellation Brands : The Mexican beer importer has been punished on fears about what Trump's tariff and immigration proposals could do to its business. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Jim Cramer's, Jim, Donald Trump's, Trump's, Abbott, Trump, Hock Tan, Tan, We'll, it's pricier, Morgan Stanley, Wells, Kamala Harris, Agentforce, That's, Biden, Dover, Eaton's, Elon, Waymo, JD Vance, we've, Linde, that's, Eli Lilly, Robert F, Kennedy Jr, Kennedy, Lilly, Mark Zuckerberg, Zuckerberg, Goldman Sachs, shouldn't, Nextracker, Brian Niccol, Niccol, Stanley Black, Decker, TJ Maxx, Wells Fargo, Jim Cramer Organizations: Jim Cramer's Charitable Trust, CNBC, Abbott Laboratories, Abbott Labs, White, Biden, AMD, Trump, Wednesday, Broadcom, VMWare, BlackRock, Costco, Coterra Energy, Coterra, DuPont, Disney, GE Healthcare, GE Aerospace, Google, Honeywell, Elliott Investment Management, Linde, Microsoft, Big Tech, Apple, Meta, Financial Times, Nvidia, Palo Alto Networks, Yum Brands, Taco Bell, Constellation Brands, Management, TJX, Marshalls, Jim Cramer's Charitable Locations: China, India, Missouri, Wells Fargo, BlackRock, Shanghai, Dover, U.S, Palo, HomeGoods

☆ I lost half my weight in 3 years. I have body dysmorphia from all the loose skin I have.
▼ + stars: | 2024-11-06 | by ( Jane Ridley | ) www.businessinsider.com time to read: +7 min

She's relieved to have gone from a 6X to a 1X — but worried about excess skin and her body image. download the app Email address Sign up By clicking “Sign Up”, you accept our Terms of Service and Privacy Policy . A sign on the wall at the weight management clinic inspires me every time I go for my body composite exam. The main reason I lost that initial weight was dental work. I often feel like I haven't lost much weight at all.

Persons: Betsy Smith, She's, —, It's, I've, I'd, Smith, Toby, Steph, I'm Organizations: Service, Business Locations: Billings , Montana

☆ JPMorgan’s favorite stock picks heading into November
▼ + stars: | 2024-11-04 | by ( Sean Conlon | ) www.cnbc.com time to read: +4 min

With the election around the corner, JPMorgan has updated its top ideas list that target growth, income, value and short-selling strategies. Yet, JPMorgan thinks that trajectory can keep going, as it has an overweight rating on the stock with a $300 price target. JPMorgan's overweight rating and target of $1,100 on the name also implies more than 34% upside from here. JPMorgan also highlighted the newly added Regency Centers as one of its growth strategies for the new trading month. Shares have jumped more than 7% this year, and JPMorgan's target implies almost 8% upside from Friday's close, on par with its average target of $77.12.

Persons: JPMorgan's, Carvana, Eli Lilly, David Ricks Organizations: JPMorgan, Nasdaq, Dow Jones Industrial, Regency Centers, Caterpillar Locations: Carvana

☆ Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
▼ + stars: | 2024-10-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Packages containing syringes of the medications Wegovy, Ozempic and Mounjaro at a shop in Mitte, Germany, July 11, 2024. Several doses of semaglutide, the active ingredient in Wegovy and Ozempic, have been on the FDA's shortage list since early 2022. In a statement, Novo Nordisk said all doses of Wegovy and Ozempic are being shipped regularly to wholesalers. Still, Novo Nordisk said patients may not always be able to immediately fill their prescriptions at a particular pharmacy, even when a medication is listed as available. "Our intentional approach to gradually increase supply into the U.S. market is working," Novo Nordisk said.

Persons: Danish drugmaker, Eli Lilly, compounders Organizations: Novo Nordisk, U.S . Food, Nordisk, FDA Locations: Mitte, Germany, U.S, Danish, Novo

☆ Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
▼ + stars: | 2024-10-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering the dip in the stock as a chance to buy. LLY .SPX 5Y mountain Eli Lilly's five-year stock performance compared with the S & P 500. Bottom line We're upgrading Eli Lilly to our buy-equivalent 1 rating and leaving our price target of $1,000 a share unchanged. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA in July, was not a major focus on the call.

Persons: Eli Lilly, Eli, Eli Lilly's, Jim Cramer, Jim, —, that's, David Ricks, Ricks, Semaglutide, Wegovy, Lilly, There's, Mounjaro, Trulicity, Verzenio, Jim Cramer's, Cristina Arias Organizations: Revenue, The Club, CNBC, JPMorgan, Novo Nordisk, Food, Novo Nordisk's, FDA, Zepbound, Biogen, Merck, Pfizer, Morphic, Company, Pharmaceutical Locations: Tuesday's, U.S, Novo, Eisai, FactSet, Zepbound, Alcobendas, Madrid, Spain

☆ Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
▼ + stars: | 2024-10-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024. During an earnings call Wednesday, Eli Lilly instead blamed it on drug wholesalers cutting inventory of Zepbound and Mounjaro. On the earnings call, Eli Lilly executives insisted that underlying demand for the medicines remained strong. No," Eli Lilly CEO Dave Ricks said, pointing instead to "a lot of lumpiness in channel stocking." Ricks said Eli Lilly had yet to begin what the company calls "demand-stimulating activities," or advertising and promoting, for Zepbound.

Persons: Eli Lilly, Mounjaro, StreetAccount ., Geoff Meacham, Jared Holz, Mizuho, Carter Gould, Eli Lilly's, tirzepatide, Dave Ricks, Ricks, Lilly Organizations: U.S, StreetAccount, Citi, Barclays, Food and Drug, FDA Locations: Brooklyn, New York, Lilly

☆ Eli Lilly stock tumbles 10% after drug giant misses estimates and slashes profit guidance
▼ + stars: | 2024-10-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, and slashed its full-year adjusted profit guidance. Eli Lilly now expects full-year adjusted earnings of between $13.02 and $13.52 per share, down from previous guidance of $16.10 to $16.60 per share. Eli Lilly also lowered the high-end of its revenue outlook for the year and now expects sales of between $45.4 billion and $46 billion. The weekly injection raked in $1.26 billion in sales for the period, below the $1.76 billion that analysts expected, according to StreetAccount. As of Wednesday, the Food and Drug Administration's drug database said all doses of Zepbound and Mounjaro are available in the U.S. after extended shortages.

Persons: Eli Lilly, Mounjaro, Eli Lilly's Organizations: Novo Nordisk, LSEG, Food Locations: U.S

☆ Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic
▼ + stars: | 2024-10-30 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantasticEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why the company is slashing its full-year adjusted profit guidance, and more.

Persons: Eli Lilly, David Ricks

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

☆ 14 earnings reports and major economic data will be the stock market movers this week
▼ + stars: | 2024-10-27 | by ( Zev Fima | ) www.cnbc.com time to read: +15 min

The Street is looking for Stanley Black & Decker sales of $3.8 billion in the third quarter and earnings per share (EPS) of $1.05. The Street is looking for Linde sales of $8.35 billion in the third quarter and EPS of $3.89. In addition to the headline results and forward guidance, overall organic sales growth and data center energy power demand will be focus items for investors. The Street is looking for sales of $94.47 billion in its fiscal fourth quarter and EPS of $1.55. The Street is looking for Coterra sales of $1.3 billion in the third quarter and EPS of 34 cents.

Persons: That's, It's, Stanley Black, Decker, we're, We're, Eli Lilly, Lilly, Amy Hood's, Brian Niccol, Wednesday's, Linde, it's, we'll, Phillips, Horton, Kraft Heinz, SIRI, Estee Lauder, BUD, Cardinal Health, Jim Cramer's, Jim Cramer, Jim, Stephanie Keith Organizations: Nasdaq, Dow, Fed, PCE, YouTube, Justice, AMD, GE Healthcare, Reality Labs, Microsoft, Management, Starbucks, U.S, Presidential, Linde, Apple Intelligence, Amazon, Services, Coterra Energy, WM, Cadence Design Systems, Labor, PayPal, BP, Pfizer, Royal Caribbean Cruises, JetBlue, HSBC, Devices, Grill, Electronic Arts, EA, Gross, Caterpillar, Brinker International, AFortive Corporation, Illinois Tool, Coinbase, eBay, EBAY, Booking Holdings, MGM Resorts, MGM, Bausch Health, LIN, Merck, ConocoPhillips, Mastercard, Altria, Cruise, Myers Squibb, Comcast, Mobileye, Cheniere Energy, Regeneron Pharmaceuticals, Anheuser, Busch InBev, Intel, United States Steel, Juniper Networks, Chevron, Exxon Mobil, Dominion Energy, Charter Communications, LyondellBasell Industries, Cardinal, Jim Cramer's Charitable, CNBC, New York Stock Exchange, Getty Locations: Eaton, Corning, Illinois, Bristol, New York City

☆ How to dance the earnings two-step: Recognize initial stock distortions and then act
▼ + stars: | 2024-10-27 | by ( Jim Cramer | ) www.cnbc.com time to read: +18 min

For all we know, the yield curve may simply be going through the birthing of an un-inverted yield curve. GOOGL YTD mountain Alphabet YTD Search used to be so simple. META YTD mountain Meta Platforms YTD Meta Platforms has run big ahead of the quarter. AMZN YTD mountain Amazon YTD Let's get to the two toughest of the week, Amazon and Apple. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: let's, Eli Lilly, nonfarm payrolls, Carl Quintanilla, batty, Jeff Marks, Waymo, Elon Musk, Donald Trump, Kamala Harris, Department's, Mark Zuckerberg, Jensen Huang, Marc Benioff, Trump, Warren Buffett, Jim Cramer's, Jim Cramer, Jim Organizations: CNBC, Microsoft, Apple, Treasury, Federal Reserve, charlatans, Honeywell, Twitter, Club, Gemini, YouTube, Google, Donner Party of cannibalization, AMD, Nvidia, Intel, Merck, Pfizer, Tech Titans, Meta, Amazon Web Services Locations: Wall, cyclicals, California, Philly

☆ Lizzo’s Halloween costume draws inspiration from ‘South Park’ episode that referenced her and the weight-loss drug Ozempic
▼ + stars: | 2024-10-26 | by ( Dan Heching | ) edition.cnn.com time to read: +2 min

CNN —Lizzo has taken a rather silly reference to her on a recent “South Park” episode and elevated it to a hilarious Halloween costume. In her first picture, Lizzo posed in an old-school-style print ad that asked, “Need self love? Lose guilt, gain self confidence.” Her caption for the post read, “Ok Halloween… you can start now.”Subsequent posts included a video snippet showing Lizzo dancing in her costume in front of a cutout of “South Park” character Cartman, as audio from the show’s Ozempic episode played. “Lizzo helps you eat everything you want and keep physical activity to a minimum… Ask about the power of not giving a f**k, with Lizzo,” the commercial adds, along with a series of side effects. Lizzo has long advocated for body positivity and spoken out about the body shaming she faces on social media.

Persons: CNN — Lizzo, Lizzo, Cartman, ”, Sharon, Sheila, “, “ Lizzo, ” “, Trey Parker, Matt Stone, CNN’s Lisa Respers Organizations: CNN, FDA, University of Colorado Boulder Locations: Colorado, Lizzo, CNN’s Lisa Respers France

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia. Another study, published in August, found that semaglutide appeared to cut the risk of dementia in people with Type 2 diabetes. Type 2 diabetes is a risk factor for dementia and Alzheimer’s. The study found that patients prescribed semaglutide had a significantly lower risk for Alzheimer’s disease than those who had taken one of the seven other diabetes drugs. The biggest difference was seen when comparing patients who took semaglutide to those who took insulin: Semaglutide patients had a 70% lower risk of Alzheimer’s, the study found.

Persons: —, semaglutide, ”, Stephen Salloway, ” Salloway, Rong Xu, liraglutide, Xu, ” Xu, they’re, Salloway, they’ve, Donna Wilcock, there’s, ” Wilcock, Dr, Alberto Espay, Espay, What’s, “, ” Espay Organizations: Alzheimer’s Association, Conference, Novo Nordisk, Warren Alpert Medical, Brown University, Center, Artificial Intelligence, Case Western Reserve University School of Medicine, Drug Administration, ”, Alzheimer’s, Indiana University School of Medicine, University of Cincinnati College of Medicine Locations: Novo, Rhode Island, Ohio

☆ Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
▼ + stars: | 2024-10-23 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy. In a statement, the agency said it is reviewing the petition and will respond directly to Novo Nordisk. The active ingredient in Wegovy and Ozempic, semaglutide, has been in intermittent shortages over the past two years. Like Novo Nordisk, Eli Lilly has sued several weight loss clinics, medical spas and compounding pharmacies across the U.S. over the past year.

Persons: Wegovy, Danish drugmaker, semaglutide, Eli Lilly, Eli Lilly's, compounders Organizations: Novo Nordisk, Tuesday, Food and Drug Administration, FDA, Nordisk Locations: Novo, Danish, U.S

☆ Lilly sues online vendors, medical spa over copycat weight-loss drugs
▼ + stars: | 2024-10-21 | by ( ) www.cnbc.com time to read: +3 min

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit. Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Lilly, MangoRx, drugmaker, Genesis Organizations: Lifestyle Medicine of, U.S . Food, Drug Administration, Genesis, FDA, B12 Locations: New York City, Lifestyle Medicine of Nevada, U.S, Indiana , Texas, Washington, Indianapolis

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in U.K.
▼ + stars: | 2024-10-16 | by ( Karen Gilchrist | Karen Gilchrist Is A Reporter For Cnbc.Com. | ) www.nbcnews.com time to read: +4 min

LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The weight-loss treatment firm and creator of Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain’s significant health challenges — including obesity. Within that, the five-year trial, conducted in collaboration with Health Innovation Manchester, will also explore how weight-loss drugs impact “participants’ employment status and sick days from work,” the company said in a news release. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, ”, Rachel Batterham, Wes Streeting, Streeting, “ It’s, ” Streeting, Peter Verdault, “, Dr, Dolly van Tulleken, Eli Lilly’s Organizations: LONDON, U.K, of Health, Social, Department for Science, Innovation, Technology, Labour government’s, Investment, National Health Services, Health Innovation, International Medical, British Health, Social Care, Covid, NHS can’t, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly, Labs Locations: Lilly, British, Europe

☆ Maine shooting survivors claim Army negligence and FDA's weight-loss drug decision: Morning Rundown
▼ + stars: | 2024-10-15 | by ( Elizabeth Robinson | Elizabeth Robinson Is A Newsletter Editor For Nbc News | Based In Los Angeles. | ) www.nbcnews.com time to read: +8 min

Supporters of then-President Donald Trump bang on glass where election absentee ballots are counted at Detroit's TCF Center on Nov. 4, 2020. Jeff Kowalsky / AFP via Getty Images fileNearly four years later, the mayhem at the TCF Center is burned into the minds of many election officials, lawyers and poll watchers. An NBC News investigation can now report the extent of the Republican Party and Trump campaign’s involvement in the TCF Center ordeal in 2020. ➡️ Former President Bill Clinton said the election will come down to whether there is a fair and transparent vote tally. ➡️ House Speaker Mike Johnson predicts the election will reflect “a demographic shift” showing larger blocs of voters helping elect Republicans.

Persons: Donald Trump, Trump, “, Jeff Kowalsky, ➡️ Harris, ”, Harris, ➡️, Bill Clinton, Mike Johnson, Robert Card, Card’s, Lilly’s, Mounjaro, wouldn’t, Eli Lilly, Bao Li, Qing Bao —, Jimmy Chin, — Elizabeth Robinson, Elizabeth Robinson Organizations: FDA, Trump, Democrat, TCF Convention, Detroit's TCF Center, Getty, TCF Center, NBC, Republican Party, RNC, Democratic, of Defense, Army, Keller Army Community Hospital, Secret Service, Zoo, Canada, Indiana, ”, Geographic, Ikea Locations: Detroit, AFP, Michigan, Erie , Pennsylvania, Maine, U.S, Lewiston , Maine, West Point , New York, North Carolina, China, Irvine, Everest

☆ Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
▼ + stars: | 2024-10-15 | by ( Karen Gilchrist | ) www.cnbc.com time to read: +4 min

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024. LONDON — U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with the U.K. The use cases for obesity drugs have been growing over recent months, with several drug regulators expanding GLP-1 drug labels for use in treating obesity-related comorbidities and other illnesses. Speaking to CNBC last week, Citi pharmaceuticals analyst Peter Verdault said the body of evidence to support increased use of weight-loss drugs "keeps coming." The company said it anticipates making an additional £279 million of new investment into the U.K. over the coming years.

Persons: Eli Lilly, Zepbound, Rachel Batterham, Lilly, Wes Streeting, Covid, Streeting, Peter Verdault, Dolly van Tulleken, Eli Lilly's Organizations: LONDON, U.K, Department of Health, Social, Department for Science, Innovation, Technology, Labour government's, Investment, National Health Services, Health Innovation, International Medical, Social Care, CNBC, Citi, MRC, University of Cambridge, BBC Radio, Lilly Locations: Brooklyn, New York, Europe

☆ Here's an earnings homework checklist so you can be ready when your companies report
▼ + stars: | 2024-10-15 | by ( Zev Fima | ) www.cnbc.com time to read: +11 min

Wells Fargo on Friday was the first portfolio name to report third-quarter results, which have been greeted enthusiastically on Wall Street. Morgan Stanley and Abbott Laboratories — both Club names as well — report earnings before Wednesday's opening bell. Revenue and earnings estimates can be found on stock ticker pages on any number of free financial websites and through brokerage account providers. Portfolio management is a must. After considering these factors, be sure to then take a higher-level portfolio management view of your investments.

Persons: Wells, Morgan Stanley, Abbott Laboratories —, Jim Cramer's, —, Eli Lilly, writeups, Stanley Black, Decker, Jim, Jim Cramer, Andrew Kelly Organizations: Abbott Laboratories, Abbott Labs, Microsoft, TJX, Palo Alto Networks, Club, Nvidia, Devices, Taiwan Semiconductor Management Company, Jim Cramer's Charitable, CNBC, Flag, New York Stock Exchange Locations: Wells Fargo, U.S

Search resuls for: "Mounjaro"

25 mentions found